3.22

1.26% 0.04

After Hours: 3.25 0.03 +0.93%

OncoCyte Corporation (OCX)

Overview News Price History Discussions Forecast Stock Split

OncoCyte Corporation stock is traded at $3.22, with a volume of 18,653. It is up +1.26% in the last 24 hours and up +25.29% over the past month. OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.

Previous Close:

$3.18

Open:

$3.21

24h Volume:

18,653

Relative Volume:

0.22

Market Cap:

$92.09M

Revenue:

$709.00K

Net Income/Loss:

$-43.14M

P/E Ratio:

-0.7093

EPS:

-4.54

Net Cash Flow:

$-20.35M

1W Performance:

-2.42%

1M Performance:

+25.29%

6M Performance:

+11.81%

1Y Performance:

+8.05%

1-Day Range:

$3.16

$3.2859

1-Week Range:

$2.96

$3.6891

52-Week Range:

$1.922

$4.75

OncoCyte Corporation Stock (OCX) Company Profile

Name

OncoCyte Corporation

Sector

Healthcare (1167)

Industry

Biotechnology (681)

Phone

510-775-0515

Address

1010 Atlantic Avenue, Suite 102, Alameda, CA

Employee

Twitter

@OncocyteCorp

Next Earnings Date

2024-11-07

Latest SEC Filings

OCX's Discussions on Twitter

Compare OCX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
OCX OncoCyte Corporation	3.22	92.09M	709.00K	-43.14M	-20.35M	-4.54
VRTX Vertex Pharmaceuticals Inc	502.55	131.41B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	635.83	72.26B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	593.47	36.20B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	271.02	35.08B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	262.60	28.24B	3.81B	-644.79M	-669.77M	-6.24

OncoCyte Corporation Stock (OCX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-24-22	Downgrade	Stephens	Overweight → Equal-Weight
Mar-14-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Jan-07-22	Initiated	Stephens	Overweight
Jan-06-22	Resumed	Piper Sandler	Overweight
Mar-17-21	Resumed	Needham	Buy
Jan-07-21	Upgrade	The Benchmark Company	Speculative Buy → Buy
Dec-16-20	Upgrade	Piper Sandler	Neutral → Overweight
Nov-30-20	Initiated	BTIG Research	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight
Jul-30-20	Reiterated	The Benchmark Company	Speculative Buy
Jul-01-20	Downgrade	Piper Sandler	Overweight → Neutral
Jun-30-20	Downgrade	Chardan Capital Markets	Buy → Neutral
Jun-02-20	Initiated	Needham	Buy
Feb-13-19	Initiated	Piper Jaffray	Overweight
Jan-29-19	Upgrade	Janney	Neutral → Buy
Dec-19-18	Resumed	Lake Street	Buy

View All

OncoCyte Corporation Stock (OCX) Latest News

Mar 26, 2025

OncoCyte (NASDAQ:OCX) Given Buy Rating at Needham & Company LLC - Defense World

Mar 26, 2025

OncoCyte (NASDAQ:OCX) Receives “Equal Weight” Rating from Stephens - Defense World

Mar 26, 2025

Mar 25, 2025

OncoCyte Corp’s Positive Earnings Call Highlights Growth - TipRanks

Mar 25, 2025

OncoCyte Corp (OCX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Regulatory ... - Yahoo Finance

Mar 25, 2025

OncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 25, 2025

Needham maintains Buy on OncoCyte, steady $4.25 target By Investing.com - Investing.com South Africa

Mar 25, 2025

Oncocyte reports progress in organ transplant diagnostics By Investing.com - Investing.com South Africa

Mar 24, 2025

Oncocyte targets $20M in recurring revenue from 20 transplant centers by 2025 - MSN

Mar 24, 2025

Earnings call transcript: OncoCyte’s Q4 2024 revenue grows, strategic advances - Investing.com

Mar 24, 2025